Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
http://www.tandfonline.com/doi/pdf/10.1080/10428190801896103
Reference17 articles.
1. The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
3. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias
4. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
5. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Cited by 225 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Calpain Small Subunit Mediated Secretion of Galectin-3 Regulates Traction Stress;Biomedicines;2024-06-04
2. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study;Clinical Lymphoma Myeloma and Leukemia;2024-06
3. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain;Blood;2024-05-23
4. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia;Hematology Reports;2024-03-12
5. Nilotinib exhibits less toxicity than imatinib and influences the immune state by modulating iNOS, p-p38 and p-JNK in LPS/IFN gamma-activated macrophages;Toxicology in Vitro;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3